The present invention concerns a skin patch, such as a dermal and/or transdermal pain relief patch comprising a backing layer (10), an adhesive layer (20), and optionally a release liner (30), said adhesive layer (20) comprising: one or more cannabinoid(s) present in an amount of 0.1-20%. Arnica extract and/or camphor in an amount of 0.2-6%, menthol in an amount of 0.2-6%, such as 0.5-5%, or 1.0-3% (by weight); and acrylates copolymer in an amount of at least 60, 70, 80, or 90% (by weight). Furthermore, a production method for such a skin patch, and different uses and/or application of such skin patches are disclosed.

The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle.

A method for producing a patch comprising a support layer and an adhesive agent layer comprises: a mixture preparation step of mixing asenapine or a pharmaceutically acceptable salt thereof with sodium acetate whose particle diameter D.sub.50 at a cumulative volume of 50% in a particle diameter distribution is 40 to 1000 m, in such a manner that the sodium acetate and sodium diacetate generated from the sodium acetate have a particle diameter D.sub.50 of 10 m or smaller, thereby obtaining a mixture containing the sodium diacetate and the asenapine or pharmaceutically acceptable salt; and an adhesive-agent-layer formation step of forming the adhesive agent layer comprising the sodium diacetate, the asenapine or pharmaceutically acceptable salt, and a pressure-sensitive adhesive base agent, by using an adhesive agent layer composition obtained by mixing the mixture with the pressure-sensitive adhesive base agent.

The invention relates generally to intradermal, transdermal, and/or transmembrane delivery of biologically active substances in the epidermis and/or through the skin, sub-dermal tissues, blood vessels and cellular membranes without causing damage to the cellular surface, tissue or membrane. The biologically active substances may have a molecular weight no less than about 5.8 kDa to about 2,500 kDa, such as Hyaluronic Acid (HA). The biologically active substances may be deposited in a dermal patch containing a red algae polysaccharide-based matrix, wherein the red algae polysaccharide is an extract of Chondrus crispus at 2% by weight of the dermal patch. The invention provides systems and methods for enhanced intradermal, transdermal, and/or transmembrane delivery of such biologically active substances using pulsed incoherent light. The invention further provides a device for the application of the pulsed incoherent light to cellular surfaces and membranes using those compositions and methods.

The present invention relates to a method of preparing a dry hydrogel sheet including the steps of: preparing a cellulose ether dispersion solution; transferring the dispersion solution to a coater while maintaining the temperature of the dispersion solution in the range of a gelation temperature of the dispersion solution to a boiling point of a dispersion medium; applying the dispersion solution transferred to the coater as a sheet; preparing a hydrogel sheet by cooling the applied dispersion solution to induce gelation; and drying the hydrogel sheet. Since the dry hydrogel sheet prepared by the method has a low moisture content, it is possible to ensure the stability of active ingredients, quantify functional components to be applied to the dry hydrogel sheet, and ensure the uniformity of the surface appearance and thickness of the dry hydrogel sheet, which results in the improvement of the quality of a final product.

Transdermal administration system comprising doxofylline as the active ingredient, for use in the treatment of bronchopulmonary diseases having a broncho-obstructive component.

A transdermal drug delivery patch according to an exemplary embodiment of the present invention includes: a flexible base layer; and a plurality of microneedle disposed at one surface of the base layer. Each of the plurality of microneedles includes a biodegradable polymer and a drug and has an empty space inside. Each of the plurality of microneedles is formed as a star-shaped pyramid including a plurality of protrusions extending in a radial direction, and a part between two protrusions adjacent along the circumferential direction among the plurality of protrusions is concave.

Continuous drug delivery systems for apixaban and other direct oral anticoagulants (DOACs).

The present invention provides an oral patch for localized treatment of mouth ulcers containing combination of tetracaine and triamcinolone as active drugs. The patch is a bilayer structure containing a drug layer with amorphous tetracaine hydrochloride and amorphous triamcinolone acetonide and a water-soluble backing layer without a drug. The oral patch with combination of drugs has improved efficacy over each individual drug. The drug layer comprises 3-20% by weight of amorphous tetracaine hydrochloride, or a pharmaceutical acceptable salt thereof, 0.1-2.0% by weight of amorphous triamcinolone acetonide or a pharmaceutical acceptable salt thereof, 20-95% by weight of a first film-forming material, 1-12% by weight of an adhesive, 1-20% by weight of one or more cooling agent, and optionally 1-12% by weight of a plasticizer. The backing layer comprises 70-95% by weight of one or more film-forming agents, 2-10% by weight of a plasticizer and optionally 1-8% by weight of a flavoring agent.

A method for producing a patch comprising a support layer and an adhesive agent layer comprises: a mixture preparation step of mixing asenapine or a pharmaceutically acceptable salt thereof with sodium acetate whose particle diameter D.sub.50 at a cumulative volume of 50% in a particle diameter distribution is 40 to 1000 m, in such a manner that the sodium acetate and sodium diacetate generated from the sodium acetate have a particle diameter D.sub.50 of 10 m or smaller, thereby obtaining a mixture containing the sodium diacetate and the asenapine or pharmaceutically acceptable salt; and an adhesive-agent-layer formation step of forming the adhesive agent layer comprising the sodium diacetate, the asenapine or pharmaceutically acceptable salt, and a pressure-sensitive adhesive base agent, by using an adhesive agent layer composition obtained by mixing the mixture with the pressure-sensitive adhesive base agent.